As more cell and gene therapies (CGT) move toward commercial production, biopharmaceutical innovators developing these potentially life-saving treatments will need reliable, fast, and efficient technologies for seamless collection, processing, and delivery. This article by Dr. Minh Hong, Mark Sawicki and Gabriela Hertz-Bruno at Lonza will examine supply chain best practices to ensure the effective manufacturing and delivery of CGTs to the patients who need them the most.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/10/Building-a-Patient-centric-CGT-Supply-Chain.pdf” width=”100%” height=”900px” style=”border:0;”]